Global Point-Of-Care Genetic Testing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In August 2022, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announced its agreement to acquire all outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A., a Warsaw, Poland-based developer of innovative technology solutions for the medical diagnostics and healthcare markets.

• In January 2023, Cipla Ltd. launched Cippoint, a point-of-care testing device capable of identifying a wide range of health conditions, including cardiac markers, diabetes, infectious diseases, fertility, and thyroid function.

The Global Point-Of-Care Genetic Testing Market is segmented across various product types, end users, and applications, each contributing to the growth and evolution of this market.Point-of-care testing (POCT) cancer kits are becoming increasingly popular due to their ability to rapidly detect and monitor cancer in a non-invasive manner. These kits are designed for the early detection of various cancers, such as breast, colorectal, and lung cancer, providing a quick, on-site diagnostic solution. The growing global prevalence of cancer and the rising emphasis on early diagnosis, coupled with an increasing demand for personalized treatment plans, are driving the expansion of this segment. POCT cancer kits are particularly beneficial in resource-limited settings where access to specialized laboratories may be limited, offering faster results that enable timely interventions.

Molecular point-of-care kits are another vital product segment, utilizing advanced technologies like PCR (Polymerase Chain Reaction) and next-generation sequencing (NGS). These kits allow for the rapid detection of genetic mutations, infections, and genetic disorders, offering high specificity and sensitivity at the point of care. The growing interest in precision medicine, where treatments are tailored based on genetic information, is a key factor fueling the demand for molecular POCT kits. These devices are beneficial not only for diagnosing genetic disorders but also for monitoring disease progression and response to treatments in real time.

The POCT in antibiotic therapies segment is experiencing growth, driven by the increasing need for rapid diagnostic tools that can identify infections and guide antibiotic prescriptions. Antibiotic resistance is a significant global health issue, and the demand for point-of-care diagnostic tests that can accurately determine the presence of bacterial infections and the appropriate antibiotic therapy is on the rise. These tests help reduce unnecessary antibiotic use and ensure more targeted treatments, contributing to better patient outcomes and the fight against antimicrobial resistance.

Assay cartridges are a critical component of POC genetic testing, enabling easy and fast testing through portable devices. These cartridges contain all the necessary reagents and materials required for a genetic test, simplifying the process and reducing the need for specialized personnel or equipment. The demand for assay cartridges is rising due to their ability to provide accurate results in various settings, including hospitals, clinics, and at-home testing. Their convenience, combined with cost-effectiveness, positions them as a key driver of the market's growth.

In terms of end users, the research laboratory segment is witnessing significant growth due to the increasing focus on genetic research, drug discovery, and the development of novel therapies. Research labs are increasingly adopting point-of-care genetic testing solutions for faster, more efficient analysis in genomic studies. Diagnostic labs also represent a crucial segment, as these labs are vital to the diagnosis of genetic conditions, infectious diseases, and various other health disorders. The ability to perform tests at the point of care allows these labs to provide faster results to healthcare providers and patients, improving decision-making and treatment strategies.

The bio-pharmaceutical industry is leveraging point-of-care genetic testing to advance drug development, personalized medicine, and clinical trials. With the growing need for precision medicine, pharmaceutical companies are increasingly utilizing genetic testing to tailor treatments to individual patients, improving efficacy and minimizing adverse reactions. Academic institutions are also adopting point-of-care genetic testing technologies, as they are crucial for teaching, research, and the development of future healthcare professionals. These institutions are at the forefront of innovation, using genetic testing to explore new therapeutic approaches and treatment modalities.

The market's applications are diverse, with drug discovery and research being one of the most prominent. Point-of-care genetic testing plays a vital role in accelerating the discovery of new drugs by providing rapid, real-time genetic information, which can guide researchers in identifying potential targets and understanding disease mechanisms. In treatment analysis, point-of-care genetic testing helps healthcare providers make data-driven decisions about the best therapeutic options based on a patient’s genetic makeup. This personalized approach to medicine is transforming how healthcare is delivered, enabling more targeted and effective treatments. Lastly, diagnosis remains a significant application area, as point-of-care genetic tests are widely used for diagnosing genetic disorders, infections, and various other diseases. The ability to obtain results quickly and accurately at the point of care improves the efficiency of healthcare systems and ensures timely interventions.

The segmentation of the Global Point-Of-Care Genetic Testing Market reveals a dynamic and rapidly evolving landscape driven by technological advancements, an increasing demand for personalized medicine, and a growing need for efficient, accessible diagnostic solutions across diverse healthcare settings.

Global Point-Of-Care Genetic Testing Segment Analysis

In this report, the Global Point-Of-Care Genetic Testing Market has been segmented by Product Type, End User, Application and Geography.

Global Point-Of-Care Genetic Testing Market, Segmentation by Product Type

In this report, the Global Point-Of-Care Genetic Testing Market has been segmented by Product Type into POCT Cancer Kits, Molecular POC Kits, POCT In Antibiotic Therapies, and Assay Cartridge.

The Global Point-Of-Care Genetic Testing Market is expanding due to innovations in testing technologies and a growing need for rapid, accessible, and accurate diagnostic tools. This market is segmented into various product types, each catering to different healthcare needs, such as POCT Cancer Kits, Molecular POC Kits, POCT in Antibiotic Therapies, and Assay Cartridges.

POCT Cancer Kits are a critical segment in the point-of-care genetic testing market, driven by the increasing global prevalence of cancer and the growing emphasis on early diagnosis. These kits enable the detection of specific cancer biomarkers at the point of care, allowing for early-stage cancer identification, monitoring, and personalized treatment strategies. They provide a significant advantage in terms of speed and convenience, offering faster results than traditional laboratory testing. With cancer being one of the leading causes of death worldwide, the demand for POCT cancer kits is anticipated to grow as healthcare systems increasingly shift towards early detection and preventative care. These kits also reduce the need for invasive biopsy procedures, making them particularly appealing for patients and healthcare providers alike.

Molecular POC Kits are a pivotal segment within this market, offering high accuracy in the detection of genetic mutations, infectious diseases, and hereditary conditions at the point of care. These kits utilize advanced molecular diagnostic techniques such as Polymerase Chain Reaction (PCR), next-generation sequencing (NGS), and CRISPR-based technology, making them suitable for a wide range of applications, including genetic disorder diagnosis, infectious disease detection, and monitoring treatment response. The molecular POC kits offer real-time, on-site testing, reducing the waiting time associated with traditional lab-based tests and providing results within hours. This quick turnaround time is crucial for initiating timely treatment, particularly in urgent conditions like infectious diseases and genetic disorders. The adoption of molecular POC kits is being fueled by the increasing demand for personalized medicine, which requires genetic data to tailor treatments to individual patients.

POCT in Antibiotic Therapies is another rapidly growing product type, driven by the increasing global concern over antibiotic resistance. These kits are designed to identify bacterial infections and help clinicians select the most appropriate antibiotic therapy for patients. By enabling rapid and accurate identification of pathogens at the point of care, POCT in antibiotic therapies helps reduce unnecessary antibiotic prescriptions, which is a key strategy in combating antimicrobial resistance. The growing awareness of antibiotic resistance and the need for targeted therapies have made POCT for antibiotic management an essential tool in both developed and developing regions. These tests help ensure that patients receive the right treatment quickly, improving patient outcomes and reducing healthcare costs.

Assay Cartridges are a fundamental part of many point-of-care genetic testing devices. These cartridges contain the necessary reagents, enzymes, and other components required for performing genetic tests, making them an essential element of the POC testing process. Assay cartridges enable portability, ease of use, and cost-effectiveness, providing a streamlined testing solution. They play a key role in the success of molecular POC kits, POCT cancer kits, and antibiotic therapy tests, as they help simplify the testing procedure while maintaining high accuracy. As the demand for user-friendly, portable diagnostic solutions increases, assay cartridges are expected to continue playing a significant role in the global market. Their widespread use is also driving innovation in terms of their design, efficiency, and the scope of genetic tests they can perform.

The segmentation of the Global Point-Of-Care Genetic Testing Market by product type highlights the diverse and dynamic nature of this market. The development of innovative, accurate, and accessible testing solutions, such as POCT cancer kits, molecular POC kits, POCT in antibiotic therapies, and assay cartridges, is revolutionizing the way genetic testing is conducted, making it faster, more affordable, and widely available. As the demand for personalized medicine, early detection, and rapid diagnostics grows, these product segments are expected to experience significant expansion in the coming years.

Global Point-Of-Care Genetic Testing Market, Segmentation by End User

In this report, the Global Point-Of-Care Genetic Testing Market has been segmented by End User into Research Laboratory, Diagnostic Labs, Bio-Pharmaceutical Industry, and Academic Institutions.

The Global Point-Of-Care Genetic Testing Market is experiencing significant growth, with various end-user segments driving demand for rapid and accessible genetic testing solutions. These end-users include research laboratories, diagnostic labs, the biopharmaceutical industry, and academic institutions, each with unique needs and applications for point-of-care genetic testing.

Research Laboratories are a key end user of point-of-care genetic testing, as they play a critical role in advancing scientific research and developing new diagnostic tools and therapies. Research labs are increasingly adopting POC genetic testing to accelerate studies on genetic diseases, cancer research, and the development of personalized medicine. The ability to conduct genetic tests at the point of care allows researchers to obtain faster results, enabling real-time data collection and analysis, which is essential for ongoing studies and clinical trials. Additionally, POC genetic testing devices help researchers to streamline the testing process, reduce time delays in obtaining results, and improve the efficiency of their work. As genetic research continues to expand and as personalized medicine becomes more prevalent, research laboratories are expected to remain a major driver of market demand.

Diagnostic Labs are another significant end user in the POC genetic testing market. These labs are central to the diagnosis of genetic disorders, infectious diseases, and other health conditions, with genetic testing being a crucial part of diagnostic procedures. Diagnostic labs utilize point-of-care genetic testing devices to provide fast, accurate, and reliable results to healthcare providers and patients. These tests allow for quicker decision-making, enabling timely diagnosis and treatment plans. With the growing need for efficient diagnostic solutions that reduce patient wait times and healthcare costs, diagnostic labs are increasingly adopting POC genetic testing to meet the demand for faster results. The ability to perform genetic tests at the point of care without the need for external laboratory facilities is particularly valuable in rural or underserved areas, where access to comprehensive diagnostic services may be limited.

The Biopharmaceutical Industry is also a major end user of point-of-care genetic testing, particularly in drug discovery, clinical trials, and the development of personalized therapies. Pharmaceutical companies are increasingly utilizing POC genetic testing to identify genetic markers that can be used to develop targeted therapies. The ability to perform genetic tests at the point of care facilitates the tailoring of treatments to individual patients, improving drug efficacy and minimizing adverse effects. This is especially important as the industry moves toward personalized medicine, where genetic information is used to create drugs that are specific to a patient's genetic profile. Furthermore, POC genetic testing is used in clinical trials to monitor patient responses and ensure that the right therapies are being administered based on genetic data. The growing demand for precision medicine and the expansion of biopharmaceutical research are expected to drive continued adoption of POC genetic testing in this sector.

Academic Institutions are also embracing point-of-care genetic testing, particularly for educational purposes, research, and the development of new technologies. Universities and other academic institutions are using these devices to train the next generation of healthcare professionals in the use of cutting-edge genetic testing technologies. Moreover, academic institutions conduct research in genetic disorders, public health, and other areas where genetic testing plays a critical role. By integrating POC genetic testing into academic curricula, institutions ensure that students and researchers are equipped with hands-on experience using modern diagnostic tools. This not only supports the academic and scientific community but also fosters innovation in genetic testing techniques and technologies, further contributing to the growth of the market. Additionally, academic research on POC genetic testing contributes to the development of more efficient, affordable, and accessible testing methods, which can be adopted in clinical and real-world settings.

The end-user segmentation of the Global Point-Of-Care Genetic Testing Market reveals a diverse range of applications across different sectors. Research laboratories are leveraging POC genetic testing for advancing studies and clinical trials; diagnostic labs are using these technologies for faster and more efficient diagnosis; the biopharmaceutical industry is utilizing them in drug development and personalized medicine; and academic institutions are incorporating them into their teaching and research activities. As the demand for faster, more accurate, and personalized diagnostic solutions continues to grow, these end-user segments are expected to drive the sustained expansion of the point-of-care genetic testing market.

Global Point-Of-Care Genetic Testing Market, Segmentation by Application

In this report, the Global Point-Of-Care Genetic Testing Market has been segmented by Application into Drug Discovery & Research, Treatment Analysis, and Diagnosis.

The Global Point-Of-Care Genetic Testing Market is being shaped by a wide range of applications, with drug discovery and research, treatment analysis, and diagnosis standing out as the primary categories driving the market’s growth. Each of these applications plays a pivotal role in revolutionizing healthcare by enabling faster, more efficient, and personalized genetic testing solutions at the point of care.

Drug Discovery & Research is a critical application of point-of-care genetic testing, particularly as the pharmaceutical and biotechnology industries continue to move towards precision medicine. Genetic testing at the point of care allows researchers to quickly identify genetic markers, mutations, and variations that are associated with specific diseases or conditions. This information is essential for identifying novel drug targets, understanding disease mechanisms, and developing new therapeutic approaches. The ability to obtain rapid genetic data in real-time accelerates the pace of drug discovery, helping to reduce the timeline for bringing new treatments to market. Additionally, point-of-care testing enables researchers to conduct more efficient clinical trials by monitoring genetic changes in patients during the trial process, facilitating more accurate assessments of drug efficacy and safety. As personalized therapies become more common, the demand for point-of-care genetic testing in drug discovery and research is expected to continue to rise, driving advancements in treatment options and improving patient outcomes.

Treatment Analysis is another key application of point-of-care genetic testing, allowing healthcare providers to make more informed decisions about the best therapeutic approaches based on a patient’s genetic profile. Genetic tests performed at the point of care provide immediate insights into how a patient might respond to specific treatments, including pharmaceuticals, biologics, and other interventions. This is especially important in fields like oncology, where genetic testing can reveal mutations that inform the selection of targeted therapies. Similarly, in fields like cardiology and neurology, point-of-care genetic testing helps identify genetic predispositions to certain conditions, enabling the development of personalized treatment regimens. Point-of-care testing also plays an essential role in pharmacogenomics, where genetic information is used to determine the best drug for a patient, minimizing adverse drug reactions and improving therapeutic efficacy. The ability to conduct treatment analysis rapidly and at the point of care is transforming how healthcare providers approach patient care, ensuring that treatments are more accurately tailored to individual genetic profiles.

Diagnosis is the most common and widely used application of point-of-care genetic testing. Diagnostic applications range from identifying genetic disorders, infectious diseases, and cancers, to screening for inherited conditions and predispositions to chronic diseases. Point-of-care testing allows for quicker, on-site diagnostics, reducing the waiting time typically associated with sending samples to centralized laboratories. This is particularly valuable in acute care settings where timely diagnosis is crucial for effective treatment. Genetic testing at the point of care is also becoming increasingly important in the early detection of conditions such as cancer, cardiovascular diseases, and neurodegenerative disorders, where early intervention can significantly improve patient outcomes. The convenience and speed of diagnosis, combined with the accuracy of genetic testing, make point-of-care genetic testing a valuable tool in improving diagnostic accuracy and facilitating immediate treatment plans. In infectious disease diagnosis, such as detecting viral or bacterial infections, point-of-care genetic tests provide healthcare professionals with the ability to quickly confirm the presence of pathogens and determine the most effective treatment course.

The application segments of drug discovery and research, treatment analysis, and diagnosis are integral to the expansion of the Global Point-Of-Care Genetic Testing Market. Drug discovery and research benefit from accelerated development processes and more precise identification of drug targets, treatment analysis enables more personalized, effective therapies, and diagnosis improves patient care by providing rapid, accurate genetic insights. The growing emphasis on personalized medicine, the need for quicker diagnostics, and the desire for more effective treatments are all driving demand for point-of-care genetic testing across these application areas. As these applications continue to evolve, they will likely continue to be major contributors to the market’s growth.

Global Point-Of-Care Genetic Testing Market, Segmentation by Geography

In this report, the Global Point-Of-Care Genetic Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Point-Of-Care Genetic Testing Market Share (%), by Geographical Region, 2024

The Global Point-Of-Care Genetic Testing Market is experiencing dynamic growth across various regions, with distinct factors driving demand in each geographic area. The market can be segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, each of which has unique drivers, challenges, and opportunities in the period from 2020 to 2030.

North America holds a significant share of the global point-of-care genetic testing market, primarily driven by advancements in healthcare infrastructure, the high adoption of advanced technologies, and a strong focus on personalized medicine. The region benefits from a robust healthcare system, substantial investments in healthcare research, and government initiatives to promote the adoption of precision medicine and genetic testing. The United States, in particular, leads the market due to its strong biopharmaceutical industry, well-established diagnostic labs, and cutting-edge research in genomics. The presence of leading companies and research institutions also accelerates innovation in genetic testing technologies, contributing to the growth of point-of-care genetic testing.

The demand for rapid diagnostic tools, especially in the wake of the COVID-19 pandemic, has further accelerated the adoption of point-of-care genetic testing in North America. Additionally, the increasing prevalence of genetic disorders, cancer, and chronic diseases is pushing for faster and more accurate diagnostic tools. The growing trend towards home-based healthcare and remote monitoring is also influencing the demand for at-home genetic testing kits. North America's market is expected to continue its strong growth trajectory through 2030, driven by technological advancements, favorable reimbursement policies, and an increasing shift toward personalized medicine.

Europe is another key region in the global point-of-care genetic testing market, with countries like Germany, France, the United Kingdom, and Italy leading the adoption of genetic testing solutions. The European market is driven by increasing awareness of genetic disorders, the rising demand for personalized treatments, and strong regulatory frameworks supporting the use of genetic testing in clinical practice. The European Union's emphasis on improving healthcare outcomes and reducing costs through early detection and prevention also plays a crucial role in accelerating market growth.

The adoption of point-of-care genetic testing in Europe is boosted by advances in molecular diagnostics, particularly in areas such as oncology and pharmacogenomics. The integration of genetic testing into routine medical practice, supported by healthcare reforms and government initiatives, is expected to drive further market expansion. However, challenges such as fragmented healthcare systems, varying reimbursement policies across countries, and regulatory barriers may limit market growth in some parts of Europe. Despite these challenges, the market is projected to grow steadily through 2030, driven by the demand for quicker, more efficient diagnostic tools and the adoption of personalized medicine in treatment regimens.

The Asia Pacific region is expected to witness the highest growth rate in the point-of-care genetic testing market during the forecast period. Key markets within this region include China, India, Japan, and South Korea. The growth in Asia Pacific is fueled by the increasing burden of genetic disorders, infectious diseases, and chronic conditions such as cancer and cardiovascular diseases. The region is also home to a rapidly growing biotechnology and healthcare sector, with increasing investments in healthcare infrastructure, diagnostic technologies, and precision medicine.

In countries like China and India, the adoption of point-of-care genetic testing is supported by the rising demand for affordable and accessible healthcare solutions in both urban and rural areas. The improvement of healthcare infrastructure, increasing healthcare expenditure, and a growing focus on genetic research and personalized medicine are expected to propel the market forward. Additionally, the rising middle-class population and the increasing prevalence of genetic disorders are key factors driving demand. However, challenges such as regulatory hurdles, limited healthcare access in rural areas, and affordability issues may impact growth. Despite these challenges, the Asia Pacific market is poised for substantial expansion, with innovations in low-cost point-of-care testing solutions expected to further fuel market growth through 2030.

The Middle East and Africa (MEA) region is a mixed market, with notable growth opportunities driven by rising healthcare investments and the increasing burden of genetic disorders, infectious diseases, and cancer. In countries such as the UAE, Saudi Arabia, and South Africa, there is growing interest in advanced healthcare technologies, including point-of-care genetic testing. The market in this region is being shaped by increasing healthcare awareness, government initiatives to improve healthcare access, and efforts to modernize healthcare infrastructure.

The MEA region faces challenges such as limited access to advanced healthcare facilities, lack of skilled professionals in genetic testing, and affordability concerns, which can restrict market growth in certain areas. Nonetheless, the increasing prevalence of genetic disorders, along with initiatives by governments and international organizations to improve healthcare access, is expected to drive growth in the region. The market will likely expand steadily through 2030, supported by investments in healthcare infrastructure and greater adoption of point-of-care testing solutions.

Latin America is expected to experience moderate growth in the point-of-care genetic testing market during the forecast period. Countries like Brazil, Mexico, and Argentina are the major contributors to the market in the region. The demand for genetic testing in Latin America is primarily driven by the increasing prevalence of chronic diseases, genetic disorders, and the rising interest in personalized medicine. Additionally, growing healthcare awareness, government healthcare initiatives, and the expansion of diagnostic services in urban areas are contributing to market growth.

Despite these positive factors, challenges such as limited access to healthcare in rural areas, affordability issues, and healthcare infrastructure gaps could hinder market expansion in certain countries. However, advancements in mobile healthcare and the rising number of public and private partnerships in the healthcare sector are expected to positively impact market growth. The Latin American market for point-of-care genetic testing is expected to expand steadily, with growth primarily driven by urbanization, the rising middle class, and increasing adoption of advanced genetic testing technologies.

The geographic analysis of the Global Point-Of-Care Genetic Testing Market reveals distinct regional trends and growth drivers. North America and Europe continue to lead in terms of market size, with strong healthcare systems, advanced research capabilities, and high adoption of personalized medicine. The Asia Pacific region is expected to experience the highest growth due to increasing healthcare investments, rising genetic disorder prevalence, and growing demand for affordable and accessible healthcare solutions. The Middle East and Africa and Latin America are projected to grow more slowly, but government initiatives and increasing healthcare infrastructure investments present opportunities for expansion through 2030.As the demand for rapid, accessible, and accurate genetic testing continues to grow worldwide, these regional markets will play critical roles in shaping the future of point-of-care genetic testing, with innovations, regulatory support, and healthcare investments driving adoption across all geographic regions.

This report provides an in depth analysis of various factors that impact the dynamics of Global Point-Of-Care Genetic Testing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Key players in Global Point-Of-Care Genetic Testing Market include,

• Cepheid
• IQuum
• Biocartis
• Abbott
• Idaho Technologies
• ThermoFisher
• Roche
• Optigene
• Lumora

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis